Ropes & Gray has advised CAMP4 Therapeutics on the transaction, and Mintz has advised the placement agents. CAMP4 Therapeutics Corporation has announced a private placement transaction...
CAMP4 Secures Up to $100 Million Through Private Placement to Fund SYNGAP1 Clinical Program
CAMP4 Therapeutics’ $75 Million IPO
Ropes & Gray represented CAMP4 Therapeutics in the transaction, and Paul Hastings represented the underwriters. CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company, announced...
CAMP4 Therapeutics’ Research Collaboration with BioMarin Pharmaceutical
Ropes & Gray advised CAMP4 Therapeutics on the transaction. CAMP4 Therapeutics Corporation, a clinical-stage biotechnology company, announced a research collaboration with BioMarin Pharmaceutical aimed at advancing...



























